NorthStar Medical Radioisotopes has inked a long-term supply agreement with Curie Therapeutics for NorthStar's actinium-225 (Ac-225) therapeutic radioisotope.
Under the deal, Curie will gain priority access to NorthStar's no-carrier-added Ac-225 therapeutic radioisotope. Curie will use Ac-225 to support development of targeted radiopharmaceuticals for treating patients with solid tumors, according to the vendors.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
